Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06571383 · ClinicalTrials.gov registry record · Phase 4
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
A Phase 4 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 4
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT06571383: Active Phase 4 study of Obesity, sponsored by Novo Nordisk A/S.
NCT06571383 is a Phase 4 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 500 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06571383, a Phase 4 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Primary Outcome
Measures as count of participants
Conditions Studied
Interventions
- DRUG Semaglutide
Study Locations (20)
Georgia
- Children's Healthcare Atlanta - Atlanta
- Columbus Research Foundation - Columbus
- Eastside Bariatric and Gen Surg - Snellville
Florida
- Clinical Neuroscience Solution - Orlando
- TMH Physician Partners Endo - Tallahassee
Ohio
- Centricity Research - Ohio - Columbus
- PriMed Clinical Research - Dayton
California
- Neighborhood Healthcare - Escondido
Idaho
- Solaris Clinical Research - Meridian
Illinois
- Synexus Clinical Research US Inc.-Chicago - Chicago
Indiana
- Indiana University Hospital - Indianapolis
Iowa
- University Of Iowa Hospitals and Clinics - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-09-17 |
| Est. Completion | 2031-11-15 |
| Phase | Phase 4 |
What the registry record for NCT06571383 still lists
NCT06571383 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide is the first listed.
NCT06571383 names 20 study sites across 16 states, led by Georgia, Florida, Ohio.
Frequently Asked Questions
What is clinical trial NCT06571383 about?
NCT06571383 is a clinical study titled "STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss". The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All...
What is the current status of trial NCT06571383?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 500 participants. The study started on 2024-09-17. Estimated completion is 2031-11-15.
What conditions does trial NCT06571383 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06571383?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06571383?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06571383 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06571383's enrollment target sits among peer trials
500 135th of 1053 higher than 911 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI